⚡ Quick Start — If You Read Nothing Else

The 8 most important things to know right now.

Friedreich ataxia is a genetic condition — not something you caused. FA is caused by an inherited expansion of GAA trinucleotide repeats in the FXN gene. Both parents must carry a copy of the altered gene for a child to be affected.
There is now an FDA-approved treatment. Omaveloxolone (Skyclarys), approved in February 2023, is the first and currently only FDA-approved therapy for FA. It works by activating the Nrf2 pathway to reduce oxidative stress, and the MOXIe trial showed it slowed neurological decline.
Cardiac disease is the leading cause of death. FA causes hypertrophic cardiomyopathy in most patients. Annual echocardiograms and cardiac monitoring are essential. If you experience chest pain, palpitations, shortness of breath, or fainting, seek emergency care immediately.
Gene therapy is in clinical trials. Multiple programs, including Lexeo Therapeutics’ LX2006 (intravenous AAV targeting cardiac involvement), aim to deliver functional copies of the FXN gene to restore frataxin protein production. These are Phase 1/2 trials — results are early but hopeful.
Rehabilitation is not optional — it is core treatment. Physical therapy, occupational therapy, and speech-language therapy directly affect quality of life and functional independence. Assistive devices matched to your functional level help maintain mobility and safety.
Diabetes screening is important. Approximately 10–30% of FA patients develop diabetes, and glucose intolerance is even more common. Regular HbA1c and oral glucose tolerance testing are recommended.
GAA repeat length matters. Longer GAA repeat expansions are associated with earlier onset, faster progression, and more severe cardiac disease. Understanding your repeat length helps your team plan monitoring and counseling.
Get to a multidisciplinary FA team. FA affects multiple organ systems simultaneously. The best outcomes come from coordinated care involving neurology, cardiology, endocrinology, orthopedics, rehabilitation, and genetic counseling — ideally at a center experienced with FA.

▼ Collapse

Understanding Friedreich Ataxia

Friedreich ataxia (FA) is the most common inherited ataxia, affecting approximately 1 in 50,000 people in populations of Indo-European descent, with roughly 5,000 patients in the United States. It is a progressive, multisystem disorder caused by a mutation in the FXN gene on chromosome 9, which leads to reduced production of a protein called frataxin.

Frataxin is essential for mitochondrial function — specifically for iron-sulfur cluster assembly and protection against oxidative stress. Without enough frataxin, cells that are most dependent on mitochondrial energy production are damaged first: nerve cells in the spinal cord and cerebellum (causing ataxia), heart muscle cells (causing cardiomyopathy), and pancreatic beta cells (causing diabetes).

FA is progressive, meaning it worsens over time. Most people with classic FA develop symptoms between ages 5 and 15, beginning with gait instability and difficulty with balance. Over years, the disease affects coordination, speech, swallowing, hearing, vision, the heart, and the endocrine system. Most patients require a wheelchair within 10–15 years of symptom onset.

Approximately 5,000 people in the United States live with Friedreich ataxia
Prevalence is approximately 1 in 50,000 in populations of Indo-European descent
FA is the most common inherited ataxia worldwide
Approximately 1 in 100 people of European descent are carriers of one copy of the FXN mutation
FA is autosomal recessive — both parents must carry the mutation for a child to be affected
FA is rare in East Asian and sub-Saharan African populations
Typical age of onset is 5–15 years, but late-onset (after 25) and very-late-onset variants exist

Classic FA: The most common form. Onset typically before age 25, with progressive gait and limb ataxia, dysarthria, absent lower limb reflexes, loss of vibration and position sense, scoliosis, and cardiomyopathy. Caused by homozygous GAA expansions (both copies of the FXN gene have expanded repeats).
Late-onset FA (LOFA): Onset after age 25. Generally slower progression and milder symptoms, but still progressive. Often associated with shorter GAA repeat expansions.
Very late-onset FA (VLOFA): Onset after age 40. Rare. Even milder course but can still develop cardiomyopathy and require monitoring.
Compound heterozygous FA: Approximately 2–4% of FA patients have one GAA expansion and one point mutation in the FXN gene. These patients may have atypical presentations depending on the specific point mutation.

The most important concept in this guide: Friedreich ataxia is a multisystem disease. It is not just a neurological condition. Your heart, endocrine system, bones, vision, and hearing are all potentially affected. The best care comes from a multidisciplinary team that monitors and treats all of these systems together — not just the ataxia.

Key Breakthroughs in FA

After decades without any approved therapy, the FA treatment landscape has begun to change. Here are the most important advances:

FDA-APPROVED Omaveloxolone is the first and currently only FDA-approved treatment for Friedreich ataxia. It activates the Nrf2 pathway, which controls the body’s antioxidant response, reducing the oxidative stress that damages cells in FA. In the pivotal MOXIe trial (NCT02255435), patients receiving omaveloxolone showed a statistically significant slowing of neurological decline compared to placebo, as measured by the modified Friedreich Ataxia Rating Scale (mFARS). Omaveloxolone is taken orally at 150 mg once daily. It requires baseline and periodic liver function tests due to a risk of hepatotoxicity, and it has significant drug interactions via the CYP3A4 pathway.

INVESTIGATIONAL Multiple gene therapy programs are underway to deliver functional copies of the FXN gene directly to affected cells using adeno-associated virus (AAV) vectors. The most advanced is LX2006 by Lexeo Therapeutics, which uses intravenous delivery to target cardiac involvement in FA — the leading cause of death in the disease. Phase 1/2 trials are actively enrolling. If successful, gene therapy could fundamentally change the course of FA by restoring frataxin production in the cells that need it most.

PRACTICE-CHANGING Echocardiography and cardiac MRI protocols now enable earlier detection and treatment of FA-related cardiomyopathy. Cardiac MRI can detect myocardial fibrosis (a marker of disease progression) before it becomes apparent on echocardiogram. Earlier detection allows earlier initiation of cardiac medications (ACE inhibitors, beta-blockers) and more informed decision-making about activity levels and surgical risks. Because cardiomyopathy is the leading cause of death in FA, these advances in monitoring are directly life-saving.

Research has now firmly established that the length of the GAA trinucleotide repeat expansion — particularly on the shorter of the two alleles (GAA1) — is the strongest predictor of disease onset, severity, and rate of progression. Longer repeats correlate with earlier onset, faster progression, and more severe cardiac disease. This allows clinicians to provide more personalized counseling about expected disease course, monitoring intensity, and timing of interventions.

Diagnosis: Getting the Right Answer

Friedreich ataxia is diagnosed through a combination of clinical evaluation and genetic testing. Because FA is relatively rare, diagnosis can be delayed — many patients see multiple doctors over several years before the correct diagnosis is made.

Progressive gait ataxia — difficulty walking, unsteadiness, frequent falls, starting in childhood or adolescence
Loss of deep tendon reflexes — particularly absent ankle and knee jerks
Loss of vibration and position sense — inability to feel vibration in the feet or tell where the toes are without looking
Dysarthria — slurred, slow, or effortful speech
Positive Babinski sign — an abnormal reflex response suggesting upper motor neuron involvement
Scoliosis — often progressive, sometimes requiring surgery
Foot deformities — pes cavus (high arches) and hammertoes are common
Hypertrophic cardiomyopathy — thickening of the heart muscle, often asymptomatic initially

The combination of progressive ataxia starting in youth, absent reflexes, and cardiomyopathy should strongly suggest FA and prompt genetic testing.

FA is definitively diagnosed by genetic testing for GAA trinucleotide repeat expansions in the FXN gene. This is a blood test that can be ordered by a neurologist or geneticist.

Normal: 5–33 GAA repeats
Premutation/borderline: 34–65 repeats (carrier status possible but does not cause disease)
Disease-causing: 66–1,700+ repeats (typically 600–1,200 in classic FA)

Approximately 96% of FA patients are homozygous — meaning they have GAA expansions on both copies of the FXN gene. The remaining 2–4% are compound heterozygotes with one GAA expansion and one point mutation. If only one expansion is found, the second copy should be sequenced for point mutations.

Frataxin protein levels can also be measured in blood (buccal cells or lymphocytes). FA patients typically have 5–30% of normal frataxin levels. This test can support the diagnosis and may be used to monitor potential treatments, but genetic testing remains the gold standard.

Echocardiogram: Baseline cardiac assessment for hypertrophic cardiomyopathy. Required at diagnosis and at least annually thereafter.
ECG (12-lead): Look for T-wave inversions, left ventricular hypertrophy, repolarization abnormalities.
Oral glucose tolerance test or HbA1c: Baseline diabetes/glucose intolerance screening.
Spine X-rays or MRI: Scoliosis assessment (Cobb angle measurement).
Audiometry: Hearing evaluation (sensorineural hearing loss occurs in some FA patients).
Ophthalmologic exam: Optic atrophy screening.
Nerve conduction studies/EMG: Axonal sensory neuropathy confirmation (if diagnosis is uncertain).
Brain and spinal MRI: May show spinal cord atrophy (cervical cord thinning) but is often normal in early disease; primarily used to exclude other diagnoses.

GAA Repeat Length — What Your Numbers Mean

The length of your GAA trinucleotide repeat expansion is the single strongest predictor of when FA will start, how quickly it will progress, and how severely the heart may be affected. FA patients inherit two expanded copies of the FXN gene (or one expansion plus a point mutation). The shorter of the two expansions (called GAA1) has the strongest correlation with disease severity.

GAA1 Length	Typical Onset	General Implications
>800 repeats	Usually before age 10	Earlier onset, faster progression, more severe cardiac disease. Wheelchair use often before age 20. Highest priority for proactive cardiac monitoring.
400–800 repeats	Typically ages 8–20	Classic FA presentation. Moderate progression rate. Cardiac monitoring essential.
<400 repeats	Often after age 15–25	Later onset, generally slower progression, retained reflexes in some patients (atypical presentation). Cardiomyopathy may still develop — do not skip cardiac monitoring.

Important: GAA repeat length is a guide, not a destiny. There is significant individual variation. Some patients with long repeats progress slowly, and some with shorter repeats develop significant cardiac disease. Repeat length helps your team plan, but it does not predict exactly what will happen to you.

Genetic Counseling — What Families Need to Know

FA is an autosomal recessive condition. This means:

Both parents of an affected individual are carriers — each carries one altered copy of the FXN gene but does not have FA themselves.
When two carriers have a child, there is a 25% (1 in 4) chance the child will have FA, a 50% chance the child will be a carrier (like the parents), and a 25% chance the child will not carry the mutation at all.
Approximately 1 in 100 people of European descent are carriers of an FXN GAA expansion.
Carrier testing is available for siblings, partners, and family members through genetic testing.

Genetic counseling is strongly recommended at diagnosis and for family planning. A genetic counselor can explain inheritance patterns, testing options for family members, and reproductive choices including preimplantation genetic testing (PGT) for couples who wish to have biological children without the risk of FA.

What are my exact GAA repeat lengths on both alleles?
Based on my repeat length, what can we expect about the pace of progression?
Do I have a compound heterozygous genotype (GAA expansion + point mutation)?
Should my siblings be tested for carrier status or FA?
Can you refer me to a genetic counselor to discuss family planning options?
What is my baseline cardiac status? When should the first echocardiogram be done?
Am I eligible for omaveloxolone (Skyclarys)?
Are there clinical trials I should consider, given my genotype and stage?
What is the current frataxin protein level in my blood?
Should I be screened for diabetes now?

Omaveloxolone (Skyclarys) — The First Approved Treatment

FDA-APPROVED Omaveloxolone (brand name Skyclarys) was approved by the FDA in February 2023 for the treatment of Friedreich ataxia in adults and adolescents aged 16 years and older. It received European Commission authorization on February 12, 2024. This marked the end of decades without any approved therapy for FA.

Omaveloxolone activates a protein called Nrf2 (nuclear factor erythroid 2-related factor 2), which is the body’s master regulator of antioxidant defenses. In FA, reduced frataxin levels lead to excess oxidative stress that damages nerve cells, heart cells, and other tissues. By boosting the Nrf2 pathway, omaveloxolone helps cells better cope with this oxidative damage.

What it does: Omaveloxolone slows the rate of neurological decline. In the MOXIe trial, patients receiving omaveloxolone showed a 2.40-point improvement in mFARS score compared to placebo over 48 weeks. While this may sound modest, in a progressive disease where decline is expected, slowing the trajectory is clinically meaningful.

What it does not do: Omaveloxolone does not restore lost function, does not increase frataxin production, and does not stop disease progression entirely. It is a disease-modifying therapy that slows decline, not a cure.

Dose: 150 mg once daily, taken on an empty stomach (at least 1 hour before or 2 hours after a meal)
Monitoring: Liver function tests (ALT, AST, bilirubin) before starting and periodically during treatment. Omaveloxolone can cause elevated liver enzymes (hepatotoxicity).
Drug interactions: Omaveloxolone is metabolized by CYP3A4. Avoid grapefruit and Seville oranges. Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) and inducers (e.g., rifampin, St. John’s wort) can significantly alter drug levels. Inform your prescriber and pharmacist about all medications and supplements.
BNP elevation: Omaveloxolone can increase B-type natriuretic peptide (BNP) levels. This is a known pharmacologic effect and does not necessarily indicate worsening heart failure, but cardiac monitoring should continue.
Side effects: Most common include elevated liver enzymes, headache, nausea, abdominal pain, fatigue, and diarrhea. Most are mild to moderate.
Cost and access: Omaveloxolone is a specialty medication. Reata Pharmaceuticals (now part of Biogen) offers patient assistance programs. Check with your insurance and the manufacturer for coverage options.

Realistic expectations. Omaveloxolone is an important advance, but it is not a cure. It slows neurological decline. It does not reverse existing damage. It is best understood as one component of a comprehensive FA management plan that also includes cardiac monitoring, rehabilitation, diabetes screening, and assistive technology.

Cardiac Management — The Most Critical Monitoring

Cardiomyopathy is the leading cause of death in Friedreich ataxia. Approximately 60–80% of FA patients develop hypertrophic cardiomyopathy (thickening of the heart muscle), and many eventually develop dilated cardiomyopathy (weakening and enlargement of the heart) as the disease progresses. Arrhythmias (abnormal heart rhythms) are also common and can be life-threatening.

Echocardiogram: At diagnosis and at least annually. More frequent if cardiomyopathy is detected or symptoms develop.
12-lead ECG: At diagnosis and annually. Look for T-wave inversions, ST changes, ventricular hypertrophy patterns, and arrhythmias.
Holter monitoring (24–48 hours): If palpitations, syncope, or arrhythmias are suspected. Atrial fibrillation and supraventricular tachycardia are the most common arrhythmias in FA.
Cardiac MRI: Consider when echocardiogram findings are borderline or when assessment of myocardial fibrosis (late gadolinium enhancement) would change management. Cardiac MRI can detect fibrosis before it is apparent on echo.
BNP/NT-proBNP: Serial monitoring of natriuretic peptides can help track cardiac function over time. Note that omaveloxolone can elevate BNP independently of cardiac status.

Cardiac management in FA follows general cardiology principles adapted for this specific population:

ACE inhibitors or ARBs: Often prescribed for ventricular remodeling and blood pressure management. Commonly used include ramipril, lisinopril, or losartan.
Beta-blockers: May be used for heart rate control, arrhythmia prevention, and in hypertrophic cardiomyopathy management. Metoprolol or bisoprolol are commonly used.
Anti-arrhythmics: If atrial fibrillation or other arrhythmias develop. Amiodarone, flecainide, or catheter ablation may be considered.
Diuretics: If heart failure symptoms (fluid retention, shortness of breath) develop.
Anticoagulation: If atrial fibrillation is detected, to reduce stroke risk.
ICD (implantable cardioverter-defibrillator): May be considered in patients with significant ventricular arrhythmias or severely reduced ejection fraction.

Important: Cardiac treatment should be managed by a cardiologist familiar with FA-specific cardiomyopathy. FA cardiomyopathy differs from other forms of hypertrophic cardiomyopathy, and standard HCM guidelines may not apply directly.

What is my current heart wall thickness and ejection fraction?
How often should I have echocardiograms?
Do I have any signs of arrhythmia? Should I have a Holter monitor?
Should I have a cardiac MRI to look for fibrosis?
Am I on the right cardiac medications for my situation?
Are there any activity restrictions I should follow?
Is my cardiologist experienced with FA-specific heart disease?
What symptoms should prompt me to go to the emergency department?

Rehabilitation & Mobility — Maintaining Independence

Rehabilitation is not supplementary in FA — it is a core treatment that directly impacts quality of life, functional independence, and safety. Physical therapy, occupational therapy, and speech-language therapy should begin early and continue throughout the disease course.

Balance and gait training: Exercises to maintain walking ability as long as possible and to improve safety when ambulating. May include treadmill training, balance boards, and task-specific practice.
Stretching and flexibility: Particularly important for preventing contractures in the ankles, hips, and shoulders as mobility decreases.
Strengthening: Targeted resistance exercises to maintain muscle strength, particularly in the core and legs. Overexertion should be avoided — FA patients fatigue more easily due to mitochondrial dysfunction.
Cardiovascular fitness: Low-to-moderate intensity exercise (adapted cycling, swimming, seated exercises) helps maintain cardiovascular health within the constraints of cardiomyopathy. Exercise intensity should be guided by cardiac status.
Fall prevention: Home safety assessments, grab bars, non-slip surfaces, and proper footwear are essential.

The right assistive device at the right time improves safety and independence. Using a mobility aid is not “giving up” — it is making a smart decision that reduces fall risk, conserves energy, and allows you to do more.

Ankle-foot orthoses (AFOs): Support the foot and ankle to improve gait stability. Often the first assistive device prescribed.
Walking poles or canes: Single-point canes or hiking poles for early balance difficulty.
Rollator walkers: Four-wheeled walkers with seats and brakes for moderate gait difficulty. Allow resting during walking.
Manual wheelchair: When walking becomes unsafe or too energy-consuming for longer distances.
Power wheelchair: When upper extremity weakness makes manual propulsion difficult. Should be fitted by a seating specialist to accommodate scoliosis and postural needs.
Vehicle modifications: Hand controls for driving, wheelchair-accessible vehicles, and ramp access.

Dysarthria (speech difficulty): Most FA patients develop slurred, slow, or effortful speech. Speech-language therapy can teach compensatory strategies, pacing techniques, and exercises to maintain intelligibility.
Communication devices: As speech becomes more difficult, augmentative and alternative communication (AAC) devices — from simple communication boards to high-tech eye-tracking systems — can maintain the ability to communicate.
Dysphagia (swallowing difficulty): FA can affect the muscles used for swallowing, increasing the risk of choking and aspiration pneumonia. A videofluoroscopic swallow study can assess risk and guide dietary modifications (thickened liquids, modified food textures).

Fine motor skills: Adaptive strategies for writing, eating, dressing, and using devices as hand coordination changes.
Home modifications: Bathroom adaptations (shower chairs, raised toilet seats), kitchen modifications (adaptive utensils, non-slip mats), and bedroom setup (hospital beds, transfer boards).
School and workplace accommodations: Occupational therapists can help identify and implement accommodations under the ADA and IDEA, including assistive technology, modified testing, and workspace adaptations.

Am I eligible for omaveloxolone? If so, what monitoring do I need?
How often should I see a physical therapist?
When is the right time to start using a mobility aid?
Should I have a swallowing assessment?
What exercises are safe given my cardiac status?
Can you refer me to a speech-language pathologist for my speech changes?
What accommodations should I request at school or work?
Are there assistive technologies that could help me right now?

Diabetes & Endocrine Management

Approximately 10–30% of FA patients develop diabetes mellitus, and a higher percentage develop impaired glucose tolerance. Diabetes in FA is caused by progressive destruction of pancreatic beta cells due to mitochondrial dysfunction and iron accumulation — similar to the mechanism that damages nerve and heart cells.

HbA1c: At diagnosis and at least annually thereafter.
Oral glucose tolerance test (OGTT): More sensitive than fasting glucose for detecting early glucose intolerance in FA. Consider at diagnosis and periodically.
Fasting glucose and insulin: Baseline and as clinically indicated.

FA-related diabetes may require insulin earlier than typical type 2 diabetes because the underlying problem is beta-cell destruction (more similar to type 1 diabetes), not just insulin resistance. Oral hypoglycemic agents may be sufficient in early stages.

Scoliosis & Orthopedic Management

Scoliosis is present in approximately 60–80% of FA patients and is often progressive. It can affect breathing, sitting posture, comfort, and wheelchair positioning. Foot deformities (pes cavus, hammertoes) are also common and can affect mobility and shoe fitting.

Monitoring: Regular spine X-rays to track Cobb angle progression, especially during growth years.
Bracing: May slow progression in skeletally immature patients with curves of 20–40 degrees.
Surgery (spinal fusion): Generally considered when the Cobb angle exceeds 40–50 degrees and is progressive. Surgical decision-making in FA must account for cardiac risk (pre-operative cardiac clearance is essential), respiratory status, and anesthetic considerations specific to FA.
Post-surgical rehabilitation: FA patients may require longer recovery and adapted rehabilitation after spinal surgery.

Pes cavus (high arches): Custom orthotic insoles, supportive shoes, and regular podiatric evaluation.
Hammertoes: Padding, shoe modifications, and surgical correction if causing pain or ulceration.
Ankle-foot orthoses (AFOs): May help with both foot positioning and gait stability.

Additional Supportive Care

Vision: Optic atrophy occurs in some FA patients. Regular ophthalmologic exams are recommended. Nystagmus (involuntary eye movements) and fixation instability are common.
Hearing: Sensorineural hearing loss and auditory neuropathy can occur. Audiometry should be performed at baseline and periodically. Hearing aids or assistive listening devices may be helpful.

Fatigue: A major symptom in FA, often underrecognized. It results from mitochondrial dysfunction, cardiac compromise, deconditioning, and the increased energy cost of movement with ataxia. Energy conservation strategies, activity pacing, and adequate sleep are important.
Pain: Musculoskeletal pain from scoliosis, abnormal gait mechanics, and joint stress is common. Neuropathic pain can also occur. Treatment approaches include physical therapy, positioning, acetaminophen, NSAIDs, and occasionally gabapentin or pregabalin for neuropathic pain.

Depression and anxiety are common in FA, as with many progressive conditions. The loss of function, social limitations, and uncertainty about the future all contribute. Psychological support, counseling, and when appropriate, medication for depression or anxiety should be offered proactively — not waited for until crisis.

Gene Therapy & Emerging Treatments

The FA treatment pipeline is the most promising it has ever been. Multiple approaches are being tested to address the underlying cause of FA — insufficient frataxin production.

INVESTIGATIONAL LX2006 is an AAV-based gene therapy designed to deliver a functional copy of the FXN gene. Lexeo Therapeutics is developing this in a Phase 1/2 clinical trial using intravenous delivery to target cardiac involvement in FA — the leading cause of death in the disease. The goal is to restore frataxin production in cardiac cells, where frataxin deficiency causes the progressive cardiomyopathy that is most immediately life-threatening. Early results are not yet available for efficacy, but safety data are being collected. Trial: NCT05445323.

INVESTIGATIONAL Nomlabofusp (formerly CTI-1601) is a protein-replacement therapy given by subcutaneous injection that delivers frataxin directly into cells — aiming to correct the root deficiency in FA. The FDA granted it Breakthrough Therapy Designation in February 2026, and Larimar Therapeutics has stated it plans to begin a rolling submission for accelerated approval in June 2026 (using skin frataxin levels as a surrogate marker), with a confirmatory global Phase 3 study ongoing. It is not yet FDA-approved — approval, if granted, would be a future event. Ask your FA specialist whether a nomlabofusp trial is an option for you.

INVESTIGATIONAL Vatiquinone is an oral drug that blocks 15-lipoxygenase to reduce oxidative stress and ferroptosis. In the Phase 3 MOVE-FA trial (NCT04577352) it did not meet its primary endpoint (mFARS change at 72 weeks), though some secondary measures favored treatment. On August 19, 2025 the FDA issued a Complete Response Letter (i.e., did not approve it), stating that an additional well-controlled study would be needed. PTC Therapeutics has said it plans a further study. It is not FDA-approved.

DISCONTINUED RT001 (developed by Retrotope) was a deuterium-stabilized form of linoleic acid designed to resist lipid peroxidation. Its Phase 2/3 FA trial (NCT04102501) did not meet its endpoints (2022), and the developer subsequently ceased operations. RT001 is no longer in active development for FA — it is included here for completeness.

INVESTIGATIONAL The GAA repeat expansion in FA silences the FXN gene through epigenetic mechanisms — specifically, the formation of abnormal DNA structures and repressive histone modifications. Several approaches aim to reverse this silencing and increase frataxin production from the patient’s own gene:

HDAC inhibitors: Histone deacetylase inhibitors can partially reactivate FXN expression. Several have been tested in preclinical and early clinical studies.
Antisense oligonucleotides (ASOs): Designed to disrupt the abnormal RNA structures formed by expanded GAA repeats, allowing normal transcription.
CRISPR-based approaches: Preclinical research is exploring whether gene editing could remove or shorten the GAA expansion, restoring normal FXN expression.

These approaches are largely in preclinical or early clinical stages.

INVESTIGATIONAL Deferiprone is an iron chelator that can cross into mitochondria, where iron accumulation is a feature of FA. The rationale is that removing excess mitochondrial iron could reduce oxidative damage. Clinical trials (including the FRDA-IIIA study) have produced mixed results — some cardiac benefit was suggested, but neurological benefit has not been demonstrated, and there is a risk of agranulocytosis (dangerously low white blood cells) requiring regular blood count monitoring. Deferiprone is not approved for FA and is considered investigational for this indication.

MIXED EVIDENCE Idebenone is a synthetic analog of coenzyme Q10 with antioxidant properties. It is NOT approved for Friedreich ataxia in any country. Santhera withdrew its US FDA application after the Phase 3 IONIA trial did not meet its primary neurological endpoint; the EMA refused a marketing authorization for FA in 2008; and Canada's earlier conditional approval (Catena) was voluntarily withdrawn in 2013 when efficacy could not be confirmed. (In Europe, idebenone/Raxone is approved only for a different condition, Leber hereditary optic neuropathy — not FA.) Some studies suggested cardiac benefit, but the neurological evidence remains negative/mixed, and idebenone is not a substitute for omaveloxolone.

Note: Idebenone is a different compound from over-the-counter CoQ10 supplements. They should not be confused or used interchangeably.

class="content-section" data-stage="advanced">

Clinical Trials — Finding and Enrolling

Clinical trials are especially important in FA because the treatment landscape is evolving rapidly, and trials offer access to promising therapies not yet commercially available. Given the small number of FA patients, every person who can participate in a trial contributes to advancing the science for the entire community.

Trial / Program	Agent	Approach	NCT Number
MOXIe (completed)	Omaveloxolone (Skyclarys)	Nrf2 activation; pivotal trial leading to FDA approval	NCT02255435
LX2006 (Lexeo Therapeutics)	AAV-FXN gene therapy	Intravenous AAV gene therapy targeting cardiac involvement	NCT05445323
Nomlabofusp	Frataxin replacement protein (SC)	Restores frataxin (Breakthrough Therapy 2026; BLA planned 2026)	search ClinicalTrials.gov
FA-COMS	Natural history study	FA Clinical Outcome Measures Study (US/Australia)	NCT03090789
EFACTS	Natural history study	European Friedreich Ataxia Consortium for Translational Studies	NCT02069509

ClinicalTrials.gov (clinicaltrials.gov): Search for “Friedreich ataxia” and filter by status (recruiting), location, and age.
FARA (Friedreich’s Ataxia Research Alliance): curefa.org — The leading patient advocacy organization for FA. Maintains a clinical trial registry, connects patients with research, and provides trial matching assistance.
National Ataxia Foundation: ataxia.org — Resources for all types of ataxia, including clinical trial information.
Your ataxia center: Ask your neurologist at an Ataxia Center of Excellence what trials they have open for your specific situation.

Do not assume trials are a “last resort.” Gene therapy and other novel approaches need participants at all stages of disease. Omaveloxolone was yesterday’s clinical trial — today’s trials may produce tomorrow’s standard treatments.

Am I eligible for the gene therapy trials currently recruiting?
Are there clinical trials at your center or nearby for my stage of FA?
What are the risks and potential benefits of the trials I might be eligible for?
Should I participate in a natural history study (FA-COMS or EFACTS)?
What emerging treatments do you think are most promising for FA?
If my cardiac disease progresses, what are the next steps?
Should I be referred to palliative care for symptom management?
What is the transition plan if I am moving from pediatric to adult care?

International Access & Regulatory Landscape

FA drug approvals and availability vary by country. This is important because the two most commonly discussed FA therapies — omaveloxolone and idebenone — have very different regulatory paths.

Drug	US FDA	EMA (Europe)	Health Canada	Notes
Omaveloxolone (Skyclarys)	Approved Feb 2023	Approved Feb 2024	Approved Mar 2025	First approved treatment for FA (Nrf2 activation); also approved UK MHRA (Apr 2025), Australia TGA (Jul 2025), Brazil ANVISA (Apr 2025) — all ages ≥16
Idebenone	NOT approved for FA	NOT approved for FA (EMA refused 2008; Raxone = LHON only)	NOT approved for FA (withdrawn 2013)	Not approved for FA in any country; FDA application withdrawn after negative IONIA trial
Deferiprone	NOT approved for FA	Not approved for FA	Not approved for FA	Approved for iron overload in thalassemia; investigational for FA
LX2006 (gene therapy)	Phase 1/2	No ex-US trials yet	Not available	US-based trial; international sites being planned
RT001	Discontinued	Discontinued	Discontinued	FA program failed (2022); developer ceased operations — no longer in development

Higher prevalence regions: FA is most common in populations of Indo-European descent, including Europe, North America, parts of India, and the Middle East (approximately 1 in 50,000).
Lower prevalence regions: FA is rare in East Asian populations (China, Japan, Korea) and sub-Saharan African populations. PMDA (Japan) and NMPA (China) regulatory pathways are generally not applicable.
Major international research networks: EFACTS (European Friedreich Ataxia Consortium for Translational Studies) and FA-COMS (FA Clinical Outcome Measures Study, US/Australia) are the two largest natural history studies harmonizing outcome measures internationally.
Australian and European trial networks are active in FA gene therapy and small molecule studies.
Carrier screening panels in European-descent populations increasingly include FXN GAA expansion analysis.

Failed & De-Adopted Therapies

Knowing what has been tried and did not work helps you evaluate new options and protects against misinformation.

MIXED RESULTS Santhera Pharmaceuticals developed idebenone for FA and conducted multiple clinical trials including IONIA (NCT00905268), MICONOS, and NICOSIA. The Phase 3 IONIA trial did not meet its primary neurological endpoint. Santhera withdrew its FDA application. Idebenone is not approved for FA in any country (EMA refused FA authorization in 2008; Canada's conditional approval was withdrawn in 2013). Some trials suggested cardiac improvement, but the neurological evidence is negative/mixed, and idebenone is NOT a substitute for omaveloxolone where available.

CAUTION While the rationale for iron chelation in FA is scientifically sound (mitochondrial iron accumulation is a feature of FA), clinical trials of deferiprone have not demonstrated clear neurological benefit. The FRDA-IIIA trial showed no improvement in neurological outcomes and raised safety concerns including agranulocytosis (severe reduction in white blood cells requiring weekly blood monitoring). Some studies suggested modest cardiac benefit at lower doses. Deferiprone is approved for iron overload in thalassemia but is not approved for FA in any major market.

INSUFFICIENT EVIDENCE Over-the-counter CoQ10 and vitamin E supplements have been widely tried by FA patients based on their antioxidant properties. However, no controlled clinical trial has demonstrated meaningful benefit for neurological or cardiac outcomes in FA. CoQ10 is not the same compound as idebenone. While these supplements are generally safe, they should not be used as a substitute for evidence-based treatments (omaveloxolone, cardiac medications, rehabilitation) and patients should not delay starting proven therapies in favor of supplements.

Why this matters: FA patients are understandably eager for any treatment that might help. Understanding what has been rigorously tested and found wanting protects against spending money and hope on unproven approaches while effective options exist. Always ask: “Has this been tested in a controlled clinical trial for FA, and what were the results?”

class="content-section" data-stage="resources">

Specialty Centers

FA outcomes are measurably better when care is coordinated by a multidisciplinary team experienced with hereditary ataxias. The following centers have established FA or ataxia programs. A second opinion from an Ataxia Center of Excellence is strongly recommended.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

University of Utah Ataxia Clinic

Specialized neurology care for hereditary ataxias including Friedreich ataxia

Location: University of Utah Health, Salt Lake City, UT
Phone: 801-585-7575
Programs: Ataxia clinic within the Department of Neurology. Genetic testing for hereditary ataxias. Coordination with University of Utah Cardiovascular Center for FA cardiomyopathy monitoring. ARUP Laboratories provides FXN GAA repeat analysis. Pediatric neurology services for childhood-onset FA.

Intermountain Health Neurology

Programs: Neurological evaluation and multidisciplinary care coordination across the Intermountain Health system in Utah and surrounding states.
Phone: 801-408-1100

University of Utah Cardiovascular Center

Programs: Cardiac monitoring for FA cardiomyopathy including echocardiography and cardiac MRI. Collaboration with the Ataxia Clinic for integrated FA care.
Phone: 801-585-7676

Utah FA connections. Utah patients can connect with the Friedreich’s Ataxia Research Alliance (FARA) for support groups, trial matching, and community events. FARA: curefa.org.

Information verified May 2026. Availability changes — confirm with each institution directly.

Children’s Hospital of Philadelphia (CHOP) — Ataxia Center of Excellence

Location: Philadelphia, PA · Phone: 215-590-1000
One of the nation’s leading FA research and clinical care centers. Active in clinical trials including gene therapy. Extensive multidisciplinary FA program. FARA-designated Ataxia Center of Excellence. Pediatric and transition-to-adult care expertise.

UCLA Ataxia Center

Location: Los Angeles, CA · Phone: 310-825-9111
Comprehensive ataxia program with dedicated FA clinic. Clinical trials, genetic testing, and multidisciplinary care. FARA-designated Ataxia Center of Excellence.

Johns Hopkins Ataxia Center

Location: Baltimore, MD · Phone: 410-955-5000
Hereditary ataxia program with research focus on FA. Clinical trials participation. Integrated neurology, cardiology, and genetics services.

Mayo Clinic — Ataxia Program

Location: Rochester, MN · Phone: 507-538-3270
Comprehensive ataxia program with expertise in FA and other hereditary ataxias. Multidisciplinary evaluation and clinical trials.

Massachusetts General Hospital — Ataxia Unit

Location: Boston, MA · Phone: 617-726-2000
Harvard-affiliated ataxia program. FA clinical trials and research. Integrated neurology and genetics.

VA Neurology Services

The VA system provides neurology care through its network of medical centers. For specialized FA care, the VA typically partners with academic ataxia centers through community care arrangements. Veterans should ask their VA neurologist about:

Referral to an academic ataxia center for second opinion and genetic testing
Community care authorization for multidisciplinary FA evaluation
Clinical trial access through VA-academic partnerships
Assistive device procurement through VA prosthetics services

VA Community Care: 1-877-881-7618

Montreal Neurological Institute (MNI) — McGill University

Location: Montréal, QC
Phone: 514-398-6644
Programs: Hereditary ataxia clinic. FA research and clinical care. Active participation in Canadian clinical trials.

Hospital for Sick Children (SickKids), Toronto

Location: Toronto, ON
Phone: 416-813-1500
Programs: Pediatric FA program. Genetic testing and multidisciplinary care for childhood-onset FA. Transition planning to adult services.

Muscular Dystrophy Canada (includes FA resources): muscle.ca

International Centers and Research Networks

Ataxia UK, London: Patient support and research funding for FA and other ataxias in the UK. ataxia.org.uk
Murdoch Children’s Research Institute, Melbourne, Australia: Leading FA research center. EFACTS and FA-COMS participant. FA registry.
Hôpital de la Pitié-Salpêtrière, Paris, France: EFACTS consortium coordinating center. FA clinical trials.
University College London (UCL) Ataxia Centre, UK: Comprehensive ataxia program including FA. Clinical trials and research.
Göttingen University Medical Center, Germany: EFACTS participant. FA genetics and clinical research.

Caregiver Guidance

Caring for someone with Friedreich ataxia is a marathon, not a sprint. FA is progressive and affects nearly every aspect of daily life over time. Caregivers — parents, siblings, partners — carry an enormous burden that must be acknowledged and supported.

Work with a physical therapist to learn proper transfer techniques and fall recovery strategies.
Conduct a home safety assessment: remove loose rugs, ensure adequate lighting, install grab bars in bathrooms, and create clear pathways.
Encourage the right mobility aid at the right time — using a walker or wheelchair is a safety decision, not a defeat.
Plan for wheelchair accessibility at home, school, and work before it becomes urgent.

FA fatigue is real and organic — it is caused by mitochondrial dysfunction, not laziness. Respect energy limits.
Help pace activities throughout the day. Avoid scheduling all demanding tasks together.
Coordinate multidisciplinary appointments to minimize travel burden (try to schedule neurology, cardiology, and therapy visits on the same day or week).
Assist with adaptive equipment setup and use — adaptive utensils, voice-activated home controls, and communication devices.

Under the ADA (Americans with Disabilities Act) and IDEA (Individuals with Disabilities Education Act), FA patients are entitled to reasonable accommodations.
Common school accommodations: extended time on tests, note-taking assistance, accessible classroom placement, assistive technology, physical therapy during school hours.
Workplace accommodations: ergonomic workspace, flexible scheduling, remote work options, accessible parking, and assistive technology.
Work with the school IEP/504 team or workplace HR department. An occupational therapist can help document specific needs.

Emotional support for the person with FA: Depression and anxiety are common. Provide access to psychological support, peer groups (FARA community, National Ataxia Foundation events), and age-appropriate independence.
Caregiver self-care: Caregiver burnout is real. Respite care, support groups (FARA family forums), counseling, and regular breaks are not optional luxuries — they are necessary.
Legal and financial planning: Early planning for disability benefits (SSI/SSDI), guardianship (if needed), special needs trusts, and healthcare power of attorney. Consult a disability attorney or social worker familiar with neurodegenerative conditions.
Transition planning: For pediatric patients, plan the transition from pediatric to adult care well in advance (ideally starting at age 14–16). Adult neurology, cardiology, and rehabilitation services should be identified before the transition occurs.

Genetic Counseling & Pregnancy in Friedreich Ataxia

Friedreich ataxia (FA) is an autosomal recessive condition, meaning a person must inherit the genetic change (the GAA repeat expansion in the FXN gene) from both parents to develop FA. Having one copy causes no symptoms but makes you a carrier.

Understanding the genetics for family planning

If you have FA: all of your children will inherit one copy of the FA gene expansion from you (making them carriers). Whether your children develop FA depends entirely on your partner. If your partner has no FA gene expansion (the most likely scenario for someone from the general population, where ~1 in 85 people are carriers), none of your children will have FA — they will all be carriers. If your partner is also a carrier, each child would have a 50% chance of having FA.
If your partner may be a carrier (family history of FA, or belongs to a higher-risk population): genetic testing for your partner is strongly recommended before pregnancy.
Preimplantation genetic testing (PGT-M): available for FA through IVF. Allows selection of embryos that have not inherited two copies of the FA expansion before implantation.
Prenatal diagnosis: chorionic villus sampling (CVS, 10-13 weeks) or amniocentesis (15-20 weeks) can test whether a pregnancy is affected.

Cardiac considerations in pregnancy

Hypertrophic cardiomyopathy (HCM) is the leading cause of early death in FA and is present in most people with FA to varying degrees. Pregnancy places significant demands on the heart. A comprehensive cardiac evaluation (ECG, echocardiogram, Holter monitoring) before conception is essential for all women with FA. Depending on cardiac function, pregnancy may carry significant risk and requires co-management by a cardiologist experienced in HCM and a maternal-fetal medicine specialist throughout pregnancy and delivery.

Physical disability and pregnancy

Increasing ataxia, weakness, and wheelchair dependence can affect the physical experience of pregnancy and delivery. Discuss with your obstetric team how mobility limitations will be managed in labor and delivery.
Scoliosis is common in FA; spinal instrumentation (if present) may affect epidural anesthesia placement — inform your anesthesiologist of surgical history.
Swallowing difficulties (dysphagia) and diabetes (FRDA-associated diabetes) require monitoring and management during pregnancy.

Medications in pregnancy

Omaveloxolone (Skyclarys): the first approved disease-modifying therapy for FA (2023, FDA). No human pregnancy data. Animal studies show developmental toxicity. Avoid in pregnancy; effective contraception required during treatment. Discuss transition planning with your neurologist well before attempting conception.
ACE inhibitors / ARBs (used for cardiac protection in HCM): contraindicated in pregnancy. Must be switched to safe alternatives (labetalol, methyldopa, or hydralazine for hypertension; discuss cardiac-safe options with cardiology) before conception.
Diabetes medications: if FRDA-associated diabetes is present, switch to insulin before conception (most oral diabetes medications are not recommended in pregnancy).

Glossary

AAV: Adeno-associated virus. A viral vector used to deliver gene therapy. Does not cause disease in humans.
Ataxia: Loss of coordination and balance caused by damage to the cerebellum or its connections. The hallmark symptom of FA.
Autosomal recessive: A pattern of inheritance where two copies of the mutated gene (one from each parent) are needed to cause disease.
BNP: B-type natriuretic peptide. A blood test used to assess heart function. Can be elevated by omaveloxolone independently of cardiac status.
Cardiomyopathy: Disease of the heart muscle. In FA, typically hypertrophic (thickening) initially, which may progress to dilated (weakening and enlargement).
Carrier: A person who has one copy of the FXN mutation but does not have FA. About 1 in 100 people of European descent are carriers.
Cobb angle: A measurement of spinal curvature on X-ray used to assess scoliosis severity. Surgery is typically considered above 40–50 degrees.
Compound heterozygote: An FA patient who has one GAA expansion and one point mutation in the FXN gene (rather than two expansions).
Dysarthria: Difficulty speaking caused by weakness or incoordination of the speech muscles. Common in FA.
Dysphagia: Difficulty swallowing. Can increase risk of choking and aspiration pneumonia.
EFACTS: European Friedreich Ataxia Consortium for Translational Studies. A major natural history study network.
FA-COMS: Friedreich Ataxia Clinical Outcome Measures Study. A US/Australia natural history study.
FARA: Friedreich’s Ataxia Research Alliance. The leading patient advocacy and research-funding organization for FA.
Frataxin: The protein produced by the FXN gene. Reduced levels of frataxin cause FA. Normal frataxin is essential for mitochondrial iron-sulfur cluster assembly.
FXN gene: The gene on chromosome 9 that encodes the protein frataxin. Mutations (GAA repeat expansions) in this gene cause FA.
GAA repeat: A trinucleotide (three-letter DNA) repeat sequence in the FXN gene. Normal: 5–33 repeats. FA: 66–1,700+ repeats.
Hypertrophic cardiomyopathy: Abnormal thickening of the heart muscle. The most common cardiac finding in FA.
Idebenone: A synthetic CoQ10 analog studied in FA but not approved for FA in any country (FDA application withdrawn; EMA refused 2008; Canada withdrawn 2013). Evidence is negative/mixed.
mFARS: Modified Friedreich Ataxia Rating Scale. A clinical assessment tool used to measure neurological disability in FA.
Mitochondria: The energy-producing structures inside cells. Mitochondrial dysfunction is the core problem in FA.
Nrf2: Nuclear factor erythroid 2-related factor 2. A protein that regulates antioxidant defenses. The target of omaveloxolone (Skyclarys).
Omaveloxolone (Skyclarys): The first and only FDA-approved treatment for FA. Activates the Nrf2 pathway to reduce oxidative stress.
Pes cavus: Abnormally high foot arches. Common in FA and can affect walking and shoe fitting.
SARA: Scale for the Assessment and Rating of Ataxia. Another clinical assessment tool for ataxia severity.
Scoliosis: Abnormal lateral curvature of the spine. Present in 60–80% of FA patients.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and major clinical care guidelines. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
FARA (Friedreich’s Ataxia Research Alliance) (curefa.org) — Patient advocacy, research funding, clinical trial matching, and community support
National Ataxia Foundation (ataxia.org) — Ataxia education, support groups, and research information
National Organization for Rare Disorders (NORD) (rarediseases.org) — Rare disease information and patient assistance programs
FDA MedWatch (fda.gov/medwatch) — Report adverse events from any medication

Key Guideline and Trial References

FARA Clinical Care Guidelines (2022): Friedreich’s Ataxia Research Alliance comprehensive care recommendations for FA management across all organ systems.
Consensus Clinical Management Guidelines for FA: Corben LA, Lynch D, Pandolfo M, et al. Consensus clinical management guidelines for Friedreich ataxia. Orphanet J Rare Dis. 2022;17(1):184.
AAN Practice Parameters for Hereditary Ataxias: American Academy of Neurology evidence-based guidelines for evaluation and management of hereditary ataxias.
MOXIe Trial: Lynch DR, Chin MP, Delatycki MB, et al. Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe study): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Ann Neurol. 2021;89(2):212–225. (NCT02255435)
IONIA Trial (idebenone): Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich’s ataxia. Arch Neurol. 2010;67(8):941–947. (NCT00905268)
ACC/AHA Guidelines for Hypertrophic Cardiomyopathy: Relevant to cardiac management in FA. American College of Cardiology / American Heart Association.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

A practical test for any online claim: If a website is making a claim about FA treatment that does not appear anywhere in PubMed, FARA’s resources, or NCCN/AAN guidelines, that should be a significant warning sign.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot diagnose, stage, or treat anyone. It does not know your GAA repeat lengths, cardiac status, functional level, comorbidities, or personal preferences. Only your medical team can build an actual plan.
FA research is advancing rapidly. Gene therapy trials, new drug targets, and guideline updates occur frequently. Every time-sensitive fact should be re-verified with your team, on FDA.gov, and on ClinicalTrials.gov.
Drug approvals and availability vary by country. This guide covers both FDA-approved and internationally available therapies, but access differs by region.
Individual outcomes cannot be predicted. GAA repeat length and other markers describe populations, not individuals. Two patients with similar genetics can have different courses.
This guide does not cover every FA-related issue. Pregnancy management, anesthetic considerations, and palliative care for advanced disease require specialized, individualized guidance from your medical team.

A final word. The FDA approval of omaveloxolone in 2023 marked a watershed moment for Friedreich ataxia after decades without any approved therapy. Multiple gene therapy programs and novel approaches now in clinical trials offer real hope for treatments that could fundamentally alter the disease course — but proactive cardiac monitoring, rehabilitation, and multidisciplinary care remain essential to the best possible outcomes today. Get to an ataxia center. Get your cardiac monitoring on schedule. Stay connected to FARA and the FA community. You are not alone. Help is real. Use it.